Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Two 14 Day Cycles of Oral Doses of Oleoyl-Estrone (MP-101) in Obese Adult Subjects

Next Previous
Trial Profile

A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Two 14 Day Cycles of Oral Doses of Oleoyl-Estrone (MP-101) in Obese Adult Subjects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2007

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oleoyl estrone (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors TG Therapeutics Inc

Most Recent Events

  • 09 Jul 2007 Results of Manhattan Pharmaceuticals' two Phase IIa obesity trials showed no statistically significant placebo adjusted weight loss for any of the treatment arms evaluated. The company will discontinue its obesity programs based on these results.
  • 09 Jul 2007 Status changed from in progress to completed.
  • 22 Feb 2007 Status change from recruiting to in progress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top